ClinicalTrials.gg
CompletedNCT03367065PERFE-CTUpdated Apr 13, 2020

Dynamic Contrast Enhancement Computed Tomography Based Technic to Assess Gastro Intestinal Wall Perfusion : Feasibility Study

An interventional study of Dynamic contrast enhanced computerised tomography in Mesenteric Ischemia and Permeability CT Technics, sponsored by Poitiers University Hospital. Completed at 1 site in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-04-13.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

This feasibility study has therefore several aims:

  1. construct a dedicated CT perfusion protocol for GIT wall perfusion;
  2. used a two-compartment pharmacokinetic model which is more adapted that a unique compartment model;
  3. from the image acquired, evaluate current parameters of perfusion including the permeability ones
02

Conditions studied

  • Mesenteric Ischemia
  • Permeability CT Technics

Browse trials for

03

In context

Mesenteric Ischemia

40 studies on the registry are indexed under Mesenteric Ischemia; 14 are open to participants now.

This study's enrollment of 10 is below the median of 110 across 14 interventional studies indexed under Mesenteric Ischemia.

Browse Mesenteric Ischemia studies →

Lead sponsor

Poitiers University Hospital is the lead sponsor of 314 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all patients over fifty years old with clinico-biological suspicion for acute GITischemia admitted at our institution

Exclusion criteria

Exclusion Criteria:

  • to contrast agent injection as so defined by the European Society of UroRadiology in 2014
  • inability to provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Dynamic contrast enhanced computerised tomography

    Radiation: Dynamic contrast enhanced computerised tomography

Interventions

  • RadiationDynamic contrast enhanced computerised tomography
06

What researchers measure

Primary outcomes

  1. number of computerised tomography with interpretable data

    Time frame: 2 hours

07

Study locations

1 site
  • Chu Poitiers
    Poitiers, Aquitaine 86000, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Nov 2017, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2016
First posted
Dec 8, 2017
StartActual
Oct 2016
Primary completionActual
Nov 2017
CompletionActual
Dec 2017
Last update
Apr 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03367065
Responsible party
Sponsor
First posted
Dec 8, 2017
Start date
Oct 2016
Primary completion
Nov 2017
Completion
Dec 2017
Last update
Apr 13, 2020

Study contacts

Guillaume HERPE, MD
principal investigator · CHU Poitiers
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion